Log In

 
Company : Business Wire 
Friday, May 31, 2002 2:25PM IST (8:55AM GMT)
 
(BW)(NONLINEAR/PERKINELMER)(PKI)
PerkinElmer Life Sciences and Nonlinear Dynamics Announce First Sale of Progenesis 2D Gel Analysis System in Pacific Rim
Global Release

Korean Sale Marks Entry into Asian Market for Gel Analysis System

PerkinElmer Life Sciences, a leading global provider of drug discovery, life science research and genetic disease screening solutions and Nonlinear Dynamics Ltd, a leading provider of innovative bioinformatics solutions Thursday announced the first sale in Asia of the Progenesis 2D gel analysis system. PerkinElmer Life Sciences has a nonexclusive distribution agreement with Nonlinear Dynamics to sell Progenesis worldwide.

The Yonsei Proteome Research Center (YPRC) at Yonsei University in Seoul, Korea has purchased two systems, which standardize the traditionally subjective process of protein spot detection in complex two-dimensional (2D) gel separations, and significantly reduce the human intervention usually required. The systems will become a key component of a fully automated clinical proteomics information database, currently under development at YPRC.

Introduced by Nonlinear Dynamics in 2001, Progenesis is the first automated gel analysis software for scientists using 2D electrophoresis in their research. Employing innovative computer algorithms that dramatically increase accuracy of spot quantitation and the detection of low concentration proteins, Progenesis addresses two of the traditional weaknesses inherent in 2D electrophoresis. Its simple user interface permits scientists to set up complex analyses of extensive series of gels in just minutes, freeing them up to perform other tasks. The Progenesis batch processor directs the entire process unattended. The system handles scanned gel images of any size and resolution in common graphic file formats.

"With our existing approach to 2D gel analysis, an experienced scientist devoted full time to visual gel review using our old software is unable to complete results for all gels now produced each week, and we know that increasing the number of people performing this task will decrease the accuracy and reproducibility of those results," said Dr. Young-Ki Paik, director of YPRC. "With Progenesis, in a few hours one person can easily handle not only our current workload of gel image analysis, but also the hundreds of gels per week we envision. This capability will allow us to achieve total automation of the critical gel analysis process in the future. And we believe the quality of our gel experiments will be markedly improved."

"YPRC recognizes the value of automated protein spot detection, sizing and location that only Progenesis can provide," said Dr. Alan Koontz, General Manager, Pacific Rim, Nonlinear Dynamics. "Progenesis is an effective means of standardizing 2D gel analysis for every scientist who participates in the Center's projects, now and in the future. YPRC is one of the leading centers for protein research in Korea. Progenesis will assure the highest confidence in the experimental information that enters its new databases, which relates particular proteins to the identification and staging of human diseases."

"We are delighted that the Yonsei Proteome Research Center has chosen the Progenesis automated gel analysis system for 2D gel analysis," said Dr. Frank Witney, president of Drug Discovery, PerkinElmer Life Sciences. "This exemplifies our strategy of providing fully integrated proteomics and drug discovery solutions to industry-leading customers in the Asian marketplace, an area we are targeting for major expansion throughout 2002 and beyond. Our goal is to help customers like YPRC automate, increase the accuracy, and improve the quality of its research processes, which will ultimately improve its overall productivity."

About The Yonsei Proteome Research Center

The Yonsei Proteome Research Center (www.proteomix.org) was established in March 2000 as a major flagship center for proteomics in Korea, and serves as a national core facility for proteomics research by providing state-of-the-art technology and collaborative relationships with major research facilities worldwide, including the Australian Proteome Analysis Facility (APAF), Proteomics Research Center of Applied Biosystems, and the Institute for Protein Research at Osaka University. Ongoing YPRC projects include the Korea 21st Century Frontier Project for proteomic screening for hepatocellular and gastric carcinomas, and the KDR Industry-University Collaboration, seeking new protein markers for metabolic diseases, aging, hypercholesterolemia, and brain tumors. YPRC's 20-member dedicated faculty have wide expertise in biochemistry, cellular and molecular biology, and cancer medicine, and are closely affiliated with Yonsei Medical Center and Yonsei College of Medicine, among Korea's premier medical institutions.

About Nonlinear Dynamics

Established in 1989, Nonlinear Dynamics is a leading worldwide provider of Bioinformatics solutions to the life science industry. The Company's innovative product portfolio comprises high-quality analysis and data mining tools for 1D and 2D electrophoresis gels and microarrays, the core technologies of Genomics and Proteomics. Nonlinear sells and supports its products through its UK headquarters, its two USA offices, and its global network of distributors and OEM resellers.
For further information please contact:

Victoria Smith (Public Relations Manager)
Nonlinear Dynamics Limited
Tyne House
26 Side
Newcastle upon Tyne
NE1 3JA
UK.
Tel: +44 191 230 2121
Fax: +44 191 230 2131.
vicki.smith@nonlinear.com;
www.nonlinear.com.

About PerkinElmer Life Sciences

PerkinElmer Life Sciences is a global provider of drug discovery, research, and clinical screening products, services and technologies for the life science industry. Incorporating Packard(R), NEN(R), and Wallac(TM) product brands, PerkinElmer Life Sciences offers a complete line of instrumentation, reagents and consumables, as well as assay development and instrumentation systems for high-throughput screening, and other areas involved in target validation for drug discovery.

For more information, contact:

PerkinElmer Life Sciences
549 Albany Street
Boston
MA
02118
USA
Telephone: (800) 551-2121 (U.S. Only)
or
+1 (617) 482-9595
Fax: +1 (617) 482-1380.
Website: www.perkinelmer.com/lifesciences.

PerkinElmer, Inc. is a global technology leader focused in three businesses - Life Sciences, Optoelectronics and Analytical Instruments. Combining operational excellence and technology expertise with an intimate understanding of our customers' needs, PerkinElmer creates innovative solutions - backed by unparalleled service and support - for customers in health sciences, communications and other markets whose applications demand precision and speed. The company operates in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

 
 
 
Submit your press release
More News from Business Wire

16/08/2018 7:11PM

Corporate Social Responsibility Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets

Following are the latest Corporate Social Responsibility news releases and story ideas available from Business Wire. These recaps, curated by Business Wire, provide reporters and bloggers around the globe instant access ...

09/08/2018 7:37PM

Corporate Social Responsibility Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets

Following are the latest Corporate Social Responsibility news releases and story ideas available from Business Wire. These recaps, curated by Business Wire, provide reporters and bloggers around the globe instant access ...

26/07/2018 6:07PM

Corporate Social Responsibility Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets

Following are the latest Corporate Social Responsibility news releases and story ideas available from Business Wire. These recaps, curated by Business Wire, provide reporters and bloggers around the globe instant access ...

Similar News

16/08/2018 2:18PM

Aster DM Healthcare Reports Q1 FY2019 Profit of Rs. 20 Crore

Aster DM Healthcare, one of the largest private healthcare service providers in multiple GCC states and an emerging healthcare player in India, today announced its financial results for the quarter ended June 30, 2018.

No Image

10/07/2018 4:22PM

Healthcare That Feels Like Homecare: Amar Ujala Group Enters the Business of Care with Ujala Healthcare

Amar Ujala Group, India’s leading integrated media company formally announced its diversification into trustworthy and inclusive healthcare.